# 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy

> **NCT05191888** · PHASE4 · UNKNOWN · sponsor: **Kaohsiung Medical University** · enrollment: 906 (estimated)

## Conditions studied

- Helicobacter Pylori Eradication

## Interventions

- **DRUG:** Vonoprazan and Amoxicillin
- **DRUG:** Vonoprazan, Amoxicillin and Clarithromycin
- **DRUG:** Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole

## Key facts

- **NCT ID:** NCT05191888
- **Lead sponsor:** Kaohsiung Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-06
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 906 (ESTIMATED)
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05191888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05191888, "14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05191888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*